AVEO Pharmaceuticals — Q4 2012 Earnings Presentation
28 slides from AVEO Pharmaceuticals's earnings presentation, Feb 13, 2013
Slide 1: AVEO 4Q12 Results Conference Call and Tivozanib Update
AVEO 4Q12 Results Conference Call and Tivozanib Update 1 February 13, 2013 Exhibit 99.1
Slide 2: Tivozanib Update: Bill Slichenmyer, MD, Chief Medical Officer
Tivozanib Update: Bill Slichenmyer, MD Chief Medical Officer 3 February 13, 2013
Slide 3: TIVO-1: Phase 3 Superiority Study of Tivozanib vs. Sorafenib
TIVO-1: Phase 3 Superiority Study of Tivozanib vs. Sorafenib as First-line Targeted Therapy for Advanced RCC
Slide 4: TIVO-1 Primary Endpoint: PFS by Independent Review
Overall TIVO-1 Primary Endpoint: PFS by Independent Review Treatment Naïve for Metastatic RCC n Median PFS (95% CI) HR P Value Tivozanib 11.9 mos (9.3-14.7) 0.797 0.042 Sorafenib 9.1 mos (7.3-9.5) n Median PFS (95% CI) HR P Value Tivozanib 12.7 mos (9.1-15.0) 0.756 0.037 Sorafenib 9.1 mos (7.3-10.8)
Slide 5: Tivozanib Safety Profile
February 12, 2013 • >1,000 subjects treated with tivozanib • Lower rates than sorafenib for common adverse events and dose modifications • Rate of fatal AEs consistent with reports from past pivotal RCC trials Dose Adjustments Motzer, et al., ASCO 2012 * Due to AE’s **Due to treatment-related AE’s T
Slide 6: 2013 ASCO GU Symposia: TIVO-1 Data Presentations
2013 ASCO GU Symposia: TIVO-1 Data Presentations
Slide 7: Overall Survival in TIVO-1: Motzer et al.
Overall Survival in TIVO-1: Motzer et al. Abstract #350
Slide 8: Protocol-Specified, Final OS Analysis
Protocol-Specified, Final OS Analysis Final OS analysis conducted, per protocol, at two years following last patient enrolled (August 2012) 0.4% 8.3% 15% 21% 28% 37% 43% 48% 53% 57% 59% 61% 67% 58% 100% % of control arm pts crossed over to tivozanib Time (months)
Slide 9: Use of Next-Line Treatments
Use of Next-Line Treatments *Other includes radiotherapy, cytokine or other therapy
Slide 10: OS in Patients from North America/Western Europe
OS in Patients from North America/Western Europe
Slide 11: Use of Next-line Therapies in North America/Western Europe
Use of Next-line Therapies in North America/Western Europe *Other includes radiotherapy, cytokine or other therapy
Slide 12: Next-line Therapy and Overall Survival
Next-line Therapy and Overall Survival Motzer, et al. Abstract #350, continued
Slide 13: Subset of Patients Who Have Received No Next-Line Therapy: 1 vs 1
Subset of Patients Who Have Received No -Line Therapy: “1 vs 1” HR=0.917 P “1 vs 1 treatment” =0.662 nd
Slide 14: Analysis of "2 vs 2" Lines of Treatment: Next-line VEGF Only
OS Analysis of “2 vs 2” Lines of Treatment: Next-line VEGF Treatment Only HR=1.37 % of patients with next-line anti-VEGF therapy 70% anti-VEGF 10% anti-VEGF P =0.382
Slide 15: Analysis of "2 vs 2" Lines of Treatment: Any Anticancer Treatment
OS Analysis of “2 vs 2” Lines of Treatment: Any Anticancer Treatment HR=1.58 P =0.027 % of patients with next-line other/VEGF/mTOR therapy 18% other 10% VEGF 8% mTOR 3% other 70% VEGF 2% mTOR
Slide 16: Tivozanib in Line Following Sorafenib: Motzer et al.
Tivozanib in 2 Line Following Sorafenib: Motzer et al. nd Abstract #364
Slide 17: Change From Baseline for Target Lesions
Change From Baseline for Target Lesions (Investigator Assessment) 141 patients had measurable disease at baseline and at least one subsequent scan *9 additional unconfirmed responses ORR (confirmed + unconfirmed) = 19% Overall Response Rate (confirmed)* = 13%
Slide 18: PFS and OS for Patients Receiving Tivozanib after Sorafenib
PFS and OS for Patients Receiving Tivozanib after Progression on Sorafenib Median PFS = 8.4 months 95% CI: 5.5-12.4 Median OS = 19.6 months 95% CI: 14.1-NA tivozanib % PFS % OS tivozanib
Slide 19: Subgroup Analyses from TIVO-1: Hutson et al.
Subgroup Analyses from TIVO-1: Hutson et al. Abstract #354
Slide 20: Forest Plot of PFS Hazard Ratios by Independent Radiological Review
Forest Plot of PFS Hazard Ratios by Independent Radiological Review Assessment a MSKCC and Heng “poor” prognostic subgroups too small to estimate HR; therefore exclude b By independent radiological review assessment
Slide 21: PFS by Prior Treatment History
PFS by Prior Treatment History Time (months) Time (months) No prior systemic therapy for metastatic disease One prior systemic therapy for metastatic disease
Slide 22: PFS in North America/Western Europe and Central Europe
PFS in North America/Western Europe and Central Europe Time (months) Time (months) Central / Eastern Europe North America / Western Europe
Slide 23: PFS by ECOG Performance Status Score
ECOG Score 0 ECOG Score 1 Time (months) Time (months) Tivozanib arm 14.8 (11.3–NR) N Median PFS (95% CI) HR P value 0.617 0.004 Sorafenib arm 9.1 (7.5–11) Tivozanib arm 9.1 (7.5–12.9) N Median PFS (95% CI) HR P value 0.920 0.588 Sorafenib arm 9 (7.2–10.9) PFS by ECOG Performance Status Score
Slide 24: PFS by MSKCC Favorable or Intermediate Score
PFS by MSKCC Favorable or Intermediate Score Time (months) Time (months) MSKCC intermediate MSKCC favorable MSKCC “poor” prognostic subgroup too small to estimate HR, therefore excluded
Slide 25: On Study BP and PFS
On-study BP, mm Hg Tivozanib Sorafenib mPFS (95% CI) n mPFS (95% CI) n P value SBP 140 SBP >140 DBP 90 DBP >90 On Study BP and PFS 9.0 (7.2–11.3) 5.8 (5.5–9.0) 0.142 16.7 (12.9–18.3) 11.1 (9.2–14.7) 0.076 9.1 (7.5–12.7) 7.3 (5.7–9.1) 0.156 18.3 (12.9–NA) 11.0 (9.3–16.4) 0.154
Slide 26: Quality of Life Results from TIVO-1: Cella et al.
Quality of Life Results from TIVO-1: Cella et al. Abstract #355
Slide 27: More Patients Experience Health-related QOL Improvement on Tivozanib
More Patients Experience Health-related QOL Improvement on Tivozanib than on Sorafenib Across Most QOL Domains • Numeric differences favoring tivozanib were observed regarding improvement rates across all subgroups and HRQoL scores, except Social Well Being (SWB). • Statistically significant differe
Slide 28: AVEO 4Q12 Results Conference Call and Tivozanib Update
AVEO 4Q12 Results Conference Call and Tivozanib Update 33 February 13, 2013